Effect of atorvastatin on hs CRP, pulmonary function and quality of life in chronic obstructive pulmonary disease  An open labeled randomized control trial

Dr. Manisha Bisht; Dr. Jagdish Rawat

Volume : VI, Issue : V, May - 2017

Effect of atorvastatin on hs CRP, pulmonary function and quality of life in chronic obstructive pulmonary disease An open labeled randomized control trial

Dr. Manisha Bisht, Dr. Jagdish Rawat

Abstract :

Objective – Beneficial effects of statins on chronic obstructive pulmonary disease have been projected in many retrospective studies, but prospective studies were lacking. So this study was done to study the efficacy of atorvastatin in improving the high sensitivity C reactive protein (hs CRP levels), pulmonary functions and quality of life in chronic obstructive pulmonary disease patients (COPD). Method– This was an open labeled interventional study conducted on 60 stable COPD patients who were having abnormal lipid profile. The patients were randomized into two groups of 30 patients each – one receiving medications for COPD and another receiving 20 mg atorvastatin along with other medications for COPD. The outcome measures were change in hs CRP levels levels, pulmonary function test and health related quality of life after 12 weeks. Results– A total of 60 participants with COPD were enrolled for the study and divided into two equal groups of 30 patients. There were 2 and 1 drop outs in atorvastatin and without atorvastatin group. After 12 weeks follow up in the atorvastatin group there was a significant improvement in the levels of hs CRP levels from 4.82 � 0.77 to 2.81� 0.73 (P<0.05) as compared to other group without atorvastatin (4.34 � 0.97 to 4.04�0.63). Mean force expiratory value in one sec (FEV1) as percent of predicted value was similar in the atorvastatin and group without atorvastatin after 12 weeks: 54 .2 �18.1 to 55.6� 17.9 (P = 0.54 ) and 55.7� 19.1 to 56.1�18.1. (P = 0.58), respectively. Both treatments had similar improvement in St George Respiratory questionnaire total score. No adverse effect was observed in the atorvastatin group. Conclusions– Atorvastatin at a daily dose of 20 mg for 12 weeks has a significant beneficial effect on the levels of high sensitivity C reactive protein in COPD patient in comparison with the other group not receiving atorvastatin. There was no effect on the pulmonary function test and quality of life scores. ( Trial registration Number – CTRI/2012/11/003162 )